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ABSTRACT:
MicroRNAs (miRNAs) are endogenous short non-coding RNA molecules that 
regulate gene expression by repressing translation or cleaving RNA transcripts in 
a sequence-specific manner. A growing body of evidence suggests that miRNAs 
are aberrantly expressed in many human cancers and that they play significant 
roles in the initiation, development and metastasis of human cancers. Genome-
wide miRNA expression signatures provide information on the aberrant expression 
of miRNAs in cancers rapidly and precisely. Recently, studies from our group and 
others revealed that microRNA-1 (miR-1), microRNA-133a (miR-133a), microRNA-
133b (miR-133b) and microRNA-206 (miR-206) are frequently downregulated in 
various types of cancers. Interestingly, miR-1-1/miR-133a-2, miR-1-2/miR-133a-1, 
and miR-206/miR-133b form homologous clusters in three different chromosomal 
regions of the human genome – 20q13.33, 18q11.2  and 6p12.2, respectively. Here 
we review recent findings  on the aberrant expression and functional significance 
of the miR-1/miR-133a and miR-206/miR-133b clusters in human cancers.
INTRODUCTION
microRNAs (miRNAs) are a class of small non-
coding RNA molecules consisting of 19–22 nucleotides 
that play important roles in a variety of biological 
processes, including development, differentiation, 
apoptosis, cell proliferation and cellular senescence [1-3]. 
miRNAs are evolutionarily conserved and located 
either within the introns or exons of protein-coding genes 
(70%) or in intergenic regions (30%) [4]. Most intronic 
and exonic miRNAs are derived from their host gene, 
suggesting that they are transcribed concurrently with their 
host transcript. The others are transcribed from intergenic 
regions or gene deserts as separate transcriptional units 
[4] (Figure 1). So far, 1527 human miRNAs have been 
registered at miRBase in release 18.0 ( http://microrna.
sanger.ac.uk/). Despite the small size of these molecules 
through several intracellular processing [5], mature 
miRNAs broadly regulate gene expression through 
translational repression and mRNA cleavage, mainly 
due to the lack of a requirement for perfect sequence 
complementarity  for target binding [6,7] (Figure 1). 
Bioinformatic predictions indicate that miRNAs regulate 
more than 30% of protein-coding genes [8]. 
The  importance  of  miRNA  in  cancer  was  first 
recognized when miRNA genes were found to be 
specifically deleted in leukemia [9]. Subsequent reports 
have shown that miRNAs are differentially expressed in 
many cancers [10]. Although the biological functions of 
miRNAs remain mostly unknown, many recent studies 
suggest that miRNAs contribute to the initiation and 
development of various types of cancer [11,12]. Recent 
reports show that some miRNAs actually control the 
condition of major cancer-related signaling molecules 
[13], such as p53 family [13,14], retinoblastoma (Rb) 
[15] and epidermal growth factor receptor (EGFR) 
[16]. MiRNAs can be separated into two main classes: 
those which are oncogenic and those which are 
tumor suppressive. Overexpressed miRNAs can act 
as oncogenes by repressing tumor suppressor genes, 
whereas underexpressed miRNAs can function as tumor 
suppressors by negatively regulating oncogenes [17-19]. Oncotarget 2012; 3:  9 - 21 10 www.impactjournals.com/oncotarget
The miR-15a and miR-16 clusters, for example, 
are well known to act as tumor suppressors by targeting 
multiple oncogenes, including BCL2, MCL1, CCND1 and 
WNT3A [20], whereas the miR-17-92 cluster (also known 
as oncomiR-1) is recognized as oncogenic [21]. Many 
cluster miRNAs have been highly conserved over the 
course of evolution [22]. These facts indicate that miRNA 
clusters involve not only in normal biological process but 
also in development of cancers .
Genes of the miR-1/miR-133a and miR-206/miR-
133b clusters
Many miRNAs are expressed in a tissue-specific 
manner, indicating that they play important roles in many 
aspects of development and physiology [1,23]. Among 
these are miR-1/133a and miR-206/133b, which are highly 
conserved in the musculatures of flies, mice and humans 
and are well characterized as muscle-specific miRNAs – 
so-called myomiRs [24,25]. miR-1-1/miR-133a-2, miR-
1-2/miR-133a-1, and miR-206/miR-133b form clusters in 
three different chromosomal regions in the human genome 
– 20q13.33, 18q11.2, and 6p12.2, respectively. miR-1-1/
miR-133a-2 is in an intron of the C20orf166 gene, miR-1-
2/miR-133a-1 is in an intron of the MIB1 gene, and miR-
206/133b is in an intergenic region (Figure 2). miR-206 
is similar to miR-1 in terms of expression and function, 
but its sequence differs from the miR-1 sequence by four 
nucleotides [26] (Figure 3). miR-133a-1 and miR-133a-2 
possess identical mature sequences. miR-133b differs 
from miR-133a by a single nucleotide at the 3’ end [26] 
(Figure 4).
It has been reported that the expression of miRNAs 
located within 50Kb of one another is highly correlated 
across 24 different human organs, suggesting that 
50Kb might be a useful functional definition of miRNA 
clusters [27]. It is not rare for miRNA clusters to have 
paralogues or homologues in other human chromosome 
regions [28]. It is well known that the miR-17-92 cluster 
(chromosome 13q31.3) has two paralogous clusters – 
miR-106a-363 (chromosome Xq26.2) and miR-106b-25 
(chromosome 7q22.1). miR-17-92 cluster function as 
oncogenes in numerous cancers [21]. On the other hand, 
miR-106b-25 acts as an important regulator of neural 
stem cell proliferation and neuronal differentiation [29]. 
The miR-23a~27a~24-2 cluster (chromosome 19p13.13) 
has one homologue – miR-23b~27b~24-1 (chromosome 
9q22.32), which are related to various human health and 
disease status [30].
Aberrant expression of miR-1, miR-133a, miR-
133b and miR-206 in cancers
Using high-throughput technology, such as miRNA 
oligonucleotide arrays and quantitative RT-PCR for 
validation, many studies have found associations between 
Figure 1: The microRNA biosynthetic pathway. miRNA genes are transcribed by RNA polymerase II (Pol II). The resulting long 
transcript is capped with a specially-modified nucleotide at the 5’ end, polyadenylated with multiple adenosines and spliced. The product 
is called primary miRNA (Pri-miRNA). Drosha crops Pri-miRNA into precursor-miRNA (Pre-miRNA). Pre-miRNA hairpins are exported 
from the nucleus to the cytoplasm by Exportin-5. In the cytoplasm, the pre-miRNA hairpin is cleaved by the RNase III enzyme Dicer. One 
strand is taken into the RNA-induced silencing complex (RISC), where the miRNA and its target interact. miRNAs that bind to mRNA 
targets with perfect matching induce mRNA cleavage, whereas translational repression is induced when matching is imperfect.Oncotarget 2012; 3:  9 - 21 11 www.impactjournals.com/oncotarget
miRNA expression levels and tumor type, grade, response 
to treatment and prognosis [31-36]. These studies indicate 
the potential for miRNAs to serve as useful markers 
of disease state and prognosis and predictors of drug 
resistance. These high-throughput analyses have found 
miR-1, miR-133a, miR-133b and miR-206 to be altered 
in various types of cancers. Except for one report about 
multiple myeloma  [37], studies on miR-1, miR-133a, 
miR-133b and miR-206 have found them all to be 
downregulated in many types of cancer (Table 1). We 
and other researchers have reported that the expression 
levels of miR-1 and miR-133a are significantly reduced 
in and correlated with maxillary sinus squamous cell 
carcinoma (SCC), renal cell carcinoma (RCC) and 
rhabdomyosarcoma (RMS) [38-40].
It is plausible that these miRNAs are silenced by 
epigenetic modification. DNA methylation-mediated miR-
1 silencing was suggested in hepatocellular carcinoma 
(HCC) after  treatment with 5-aza-cytidine [41], and 
methylation of an miR-1-1 promoter CpG island has been 
found frequently in primary colorectal cancer (CRC) 
and colorectal adenoma [42]. In lung cancer cells, miR-
1 suppression might be caused by hypoacetylation of 
nucleosomal histones and not DNA methylation [43].
With regard to expression levels in tumor tissues, 
high expression levels of miR-133b were found to be 
associated with poor prognosis for progression free 
survival in 106 patients with bladder cancer (BC) [44]. 
In contrast, low expression levels of miR-133b in tumor 
tissues were found to be associated with poor prognosis 
for overall survival (n=43) and positive lymph node 
metastasis (n=45) in CRC [45]. In RMS, low expression 
levels of miR-206 in tumor tissues were shown to be 
correlated with poor prognosis for overall survival 
(n=159), but no difference was found in the expression 
levels of miR-1 [46].
Figure 2: Gene structure of the human miR-1/133a and miR-206/133b clusters.(A) miR-1-1 and miR-133a-2 are in an   
intron of the C20orf166 gene on human chromosome 20q13.33, where they are separated by 10.5kb. (B) miR-1-2 and miR-133a-1 are in a 
complementary strand of an intron of the MIB1 gene on human chromosome 18q11.2, where they are separated by 3.2kb.(C) miR-206 and 
miR-133b are clustered together on human chromosome 6p12.2, where they are separated by 4.5kb. 
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Circulating miR-1, miR-133a, miR-133b and miR-
206 as potential diagnostic markers
As noninvasive diagnostic tools, serum miRNAs 
have the potential to be fingerprints for diseases because 
human serum and plasma contain a number of stable 
miRNAs, and the differential expression patterns of serum 
miRNAs are intrinsic to a specific disease [47,48]. miR-1 
may serve as a predictor for overall survival in non-small 
cell lung cancer (NSCLC). Low serum expression levels 
of miR-1 were found to be associated with poor prognosis 
in NSCLC [49]. Similarly, miR-206 expression levels in 
serum might be used to distinguish RMS from non-RMS 
tumors (sensitivity of 1.0 and specificity of 0.913) [50]. 
In a study of gastric cancer (GC), a combination of five 
serum miRNAs (miR-1, miR-20a, miR-27a, miR-34 
and miR-423) was a better indicator for cancer detection 
than conventional markers, such as CEA and CA19-9 
(sensitivity of 0.8 and specificity of 0.81) [51]. Expression 
of these five serum miRNAs was significantly higher in 
GC patients. Moreover, risk score values based on the 
expression  of  the  five  serum  miRNAs  was  positively 
correlated with clinical stage [51].
Functional significance of miR-1, miR-133a, miR-
133b and miR-206 in cancers
As miR-1, miR-133a, miR-133b and miR-206 
are mostly downregulated in cancers, gain-of-function 
experiments are a feasible way to evaluate the functional 
significance of these miRNAs in various cancers.
Ectopic expression of miR-1 reportedly inhibits 
cell growth in HCC [41], RMS [40,52], lung cancer [43], 
maxillary sinus SCC [38], head and neck squamous cell 
carcinoma (HNSCC) [53], laryngeal SCC [54], thyroid 
cancer [55-57], prostate cancer (PCa) [58], BC [59], RCC 
[39] and CRC [42]. miR-1 overexpression has also been 
reported to induce apoptosis through enhanced activation 
of caspases 3 and 7 and cleavage of their substrate, PARP-
1, in lung cancer cells [43]. Our group also revealed that 
miR-1 overexpression induces apoptosis in maxillary 
sinus SCC [38], HNSCC [53], BC [59] and RCC cells [39] 
by fluorescence-activated cell sorting (FACS) analysis. 
FACS, TdT-mediated dUTP nick end labeling (TUNEL) 
and caspase assays revealed that miR-1 induces apoptosis 
in nasopharyngeal carcinoma cells [60]. As for cell cycle 
distribution, miR-1 was found to induce G0/G1 arrest 
Table 1: Altered expression of miR-1, miR-133a, miR-133b and miR-206 in cancers
Type of Cancer 1 133a 133b 206 Reference
HNSCC D D D - [53,74,78,83]
Maxillary sinus SCC D D - - [38]
Tongue SCC - D D - [68]
Hypopharyngeal SCC D - - - [84] 
Esophageal SCC D D D - [69]
Thyroid cancer D - - - [56,57]
Lung SCC - D - D [67]
Lung cancer D - D D [43,79]
Gastric cancer - - D - [85]
PDAC - D - - [86]
HCC D - - - [41]
RCC D D - - [39]
Bladder cancer D D D - [59,87]
Prostate cancer D D - - [58,88]
Colorectal cancer D D D - [42,70,89-91]
Rhabdomyosarcoma D D - D [40,46,52,62]
ERα positive breast cancer - - - D* [64]
ERα positive  EEC - - - D* [65]
Multiple Myeloma U U - - [37]
*: Compared with ERα negative cancer
D: Downregulated, U: Upregulated, SCC: squamous cell carcinoma
HNSCC: head and neck squamous cell carcinoma, PDAC: pancreatic ductal 
adenocarcinoma, HCC: hepatocellular carcinoma, RCC: Renal cell carcinoma
ERα: estrogen receptor alpha, EEC: endometorial endometorioid carcinomaOncotarget 2012; 3:  9 - 21 13 www.impactjournals.com/oncotarget
in lung cancer [43], HNSCC [53], RCC [39] and RMS 
cells [40,52] and G2 arrest in HCC cells [41]. Evaluations 
of cell migration and invasion activities have also been 
conducted by wound healing assay, Boyden chamber 
assay and invasion chamber assay. miR-1 has been found 
to inhibit cancer cell migration and invasion in lung cancer 
[43], thyroid cancer [56], HNSCC [53], laryngeal SCC 
[54], BC [59], RCC [39], PCa [58], RMS [52] and CRC 
cells [42]. In vivo, a tumor suppressive function for miR-1 
was shown in lung cancer and RMS in xenotransplanted 
mice [43,52].
In acute myeloid leukemia (AML) cell lines, 
overexpression of miR-1 promotes cell proliferation, 
suggesting that miR-1 might act as an oncogene in 
hematologic malignancy [61]. It is interesting to note 
that the commonalities and differences in miR-1 function 
Figure 3: Alignment of miR-1-1, miR-1-2 and miR-206. The structures of precursor miR-1-1, miR-1-2 and miR-206 as constructed 
by the Mfold program [92] (http://mfold.rna.albany.edu/). The respective Pre-miRNA sequences were entered into the program. Each 
mature miRNA sequence is shown below with red characters indicating variant nucleotides.
miR-1    : UGGAAUGUAAAGAAGUAUGUAU
miR-206: UGGAAUGUAAGGAAGUGUGUGG
hsa-miR-1-1 hsa-miR-1-2 hsa-miR-206Oncotarget 2012; 3:  9 - 21 14 www.impactjournals.com/oncotarget
depend on the type of malignant cells.
With regard to miR-206, a homologue of miR-1, 
the articles of its functional role are reported in RMS, 
breast cancer, endometrial endometorioid carcinoma 
(EEC) and lung cancer. Ectopic miR-206 expression 
inhibits cell growth in RMS [46,52,62], breast cancer 
[63,64], EEC [65] and lung cancer cells [66]. Moreover, 
FACS analysis revealed that miR-206 induced apoptosis 
in RMS [46,52,62], EEC [65] and lung cancer cells [66], 
and induced G0/G1 arrest in RMS [46,52,62], breast 
[63] and lung cancer cells [66]. Cell migration and 
invasion activities are also inhibited by miR-206 in RMS 
[46,52,62], EEC [65] and lung cancer cells [66]. In RMS 
cells, miR-206 increased the number of myosin heavy 
chain (MHC)-positive cells, which means that miR-206 
induced myogenic differentiation in RMS cells. Consistent 
with these results, miR-206 suppressed the expression 
of cyclin D1 and phospho-retinoblastoma protein and 
upregulated p21 and myogenin [62]. In vivo, a tumor 
suppressive function for miR-206 has been shown in RMS 
in xenotransplanted mice [62].
Ectopic miR-133a has been shown to inhibit cancer 
cell growth in lung SCC [67], maxillary sinus SCC [38], 
tongue SCC [68], esophageal squamous cell carcinoma 
(ESCC) [69], PCa [58], BC [59], RCC [39] and RMS 
[40], and miR-133a was found to induce apoptosis in 
maxillary sinus SCC [38], tongue SCC [68], BC [59], and 
RCC cells [39], whereas miR-133a induced G2 arrest in 
RCC cells [39]. Cell migration and invasion activities are 
also inhibited by miR-133a in ESCC [69], PCa [58], BC 
Figure 4: Alignment of miR-133a-1, miR-133a-2 and miR-133b. The structures of precursor miR-133a-1, miR-133a-2 and miR-
133b as constructed by the Mfold program [92] (http://mfold.rna.albany.edu/). The respective Pre-miRNA sequences were entered into the 
program. Each mature miRNA sequence is shown below with red characters indicating variant nucleotides.
miR-133a: UUUGGUCCCCUUCAACCAGCUG
miR-133b: UUUGGUCCCCUUCAACCAGCUA
hsa-miR-133a-2 hsa-miR-133a-1 hsa-miR-133bOncotarget 2012; 3:  9 - 21 15 www.impactjournals.com/oncotarget
[59] and RCC [39]. miR-133b, a homologue of miR-133a, 
also inhibited tumor growth in tongue SCC [68], ESCC 
[69], and CRC cells [70]. Overexpression of miR-133b 
has been shown to induce apoptosis and G1 cell cycle 
arrest in CRC cells [70], whereas cell invasion activity 
was inhibited by miR-133b in ESCC cells [69]. In vivo, 
a tumor suppressive function for miR-133b was shown in 
CRC in xenotransplanted mice [70].
miR-1-, miR-133a-, miR-133b- and miR-206-
regulated molecular networks in cancers
Each miRNA theoretically has the potential to 
regulate a number of specific mRNAs, as the recognition of 
miRNA targets depends on the sequence complementarity 
of seed regions, which have lengths of about 7 nucleotides 
[1]. Several optimized experimental approaches can lead 
to identify actual miRNA target genes in a presented cell 
phenotype [71]. Conducting qPCR, western blotting, 
and reporter assays and using bioinformatic prediction 
programs, recent research has identified several targets 
of miR-1, miR-133a, miR-133b and miR-206 (Table 2). 
These targets potentially contribute to specific functional 
readouts of miR-1, miR-133a, miR-133b and miR-206. 
For example, the tumor suppressive function of miR-1 is 
partially accounted for by its repression of the oncogenic 
target met proto-oncogene (MET) in lung cancer [43], 
HCC [41], papillary thyroid cancer [57] and RMS [52]. To 
our knowledge, other validated oncogenic targets of miR-1 
are forkhead box P1 (FOXP1) and histone deacetylase 4 
(HDAC4) in lung cancer [43] and HCC [41]; LIM and SH3 
protein 1 (LASP1) in BC [72]; pim-1 oncogene (PIM1) in 
lung cancer [43]; cyclin D2 (CCND2), chemokine (C-X-C 
motif) receptor 4 (CXCR4) and chemokine (C-X-C motif) 
ligand 12 (CXCL12) in thyroid cancer [56]; purine 
nucleoside phosphorylase (PNP) in maxillary sinus SCC 
[38] and PCa [58]; transgelin 2 (TAGLN2) in maxillary 
Figure 5: Workflow for the bioinformatic analysis of target genes of miR-1, miR-133a, miR-133b and miR-206. A total 
of 3716 genes were identified by the TargetScan program as predicted targets of miR-1, miR-133a, miR-133b and miR-206. The predicted 
target genes of miR-1 are the same as those of miR-206, and those of miR-133a are the same as those of miR-133b, due to the identical 
sequences of their seed regions. The genes were then analyzed and characterized in KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathway categories [93] by the GENECODIS program (Left). Twenty significantly enriched signaling pathways are shown in descending 
order of the number of genes contained in each pathway (Right).
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sinus SCC [38]; HNSCC [53], BC [59] RCC [39], and 
prothymosin alpha (PTMA) in nasopharyngeal carcinoma 
[60];  fibronectin  1  (FN1)  in  laryngeal  SCC  [54];  and 
splicing factor arginine/serine-rich 9 (SRSF9) in BC [73]. 
Validated targets of miR-133a are actin-related protein 2/3 
complex, subunit 5 (ARPC5) in lung SCC [67]; caveolin 
1 (CAV1) in HNSCC [74]; fascin homolog 1 (FSCN1) in 
BC [75] and ESCC [69]; glutathione S-transferase pi 1 
(GSTP1) in HNSCC [76] and BC [77]; LASP1 in BC [72]; 
pyruvate kinase, muscle (PKM2) in tongue SCC [78]; PNP 
in maxillary sinus SCC [38] and PCa [58]; and TAGLN2 
in maxillary sinus SCC [38] and BC [59]. miR-133b 
targets MET in CRC cells [70]; PKM2 in tongue SCC 
[68]; FSCN1 in ESCC [69] and myeloid cell leukemia 
sequence 1 (MCL1); and BCL2-like 2 (BCL2L2) in lung 
cancer [79]. MCL1 is also indirectly suppressed by miR-1 
in lung cancer [43]. Target genes of miR-206 are MET in 
RMS [52,62]; estrogen receptor 1 (ESR1, alias; ERα) in 
breast cancer [63] and EEC [65]; and notch 3 (NOTCH3) 
in HeLa cells [80]. As mentioned above, although the 
sequence of each seed region is different, some targets, 
such as MET, TAGLN2, PNP and LASP1, are commonly 
regulated by the miR-1/miR-133a and/or miR-206/miR-
133b clusters. In addition, TargetScan, an miRNA target 
prediction program (http://www.targetscan.org/), has 
revealed, interestingly, that the miR-1 targets; FOXP1 and 
Table 2: Validated oncogene targets of miR-1, miR-133 and miR-206 in cancers
miRNA Symbol Gene name Reference
1 CCND2 cyclin D2 [56]
CREB1 cAMP-responsive element binding protein 1 [55]
CXCL12 chemokine (C-X-C motif) ligand 12 [56]
CXCR4 chemokine (C-X-C motif) receptor 4 [56]
FN1 fibronectin 1 [54]
FOXP1 forkhead box P1 [41,43]
HDAC4 histone deacetylase 4 [41,43]
LASP1 LIM and SH3 protein 1 [72]
MET met proto-oncogene [41,43,52,57]
PIM1 pim-1 oncogene [43]
PNP purine nucleoside phosphorylase [38,58]
PTMA prothymosin alpha [60]
SRSF9 splicing factor arginine/serine-rich 9 [73]
TAGLN2 transgelin 2 [38,39,53,59]
133a ARPC5 actin-related protein 2/3 complex, subunit 5 [67]
CAV1 caveolin 1, caveolae protein, 22kDa [74]
FSCN1 fascin homolog 1, actin-bundling protein [69,75]
GSTP1 glutathione S-transferase pi 1 [76,77]
LASP1 LIM and SH3 protein 1 [72]
PKM2 pyruvate kinase, muscle [68]
PNP purine nucleoside phosphorylase [38,58]
TAGLN2 transgelin 2 [38,39,53,59]
133b BCL2L2 BCL2-like 2 [79]
FSCN1 fascin homolog 1, actin-bundling protein [69]
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) [79]
MET met proto-oncogene  [70]
PKM2 pyruvate kinase, muscle [68]
206 ESR1 estrogen receptor 1 [63,65]
MET met proto-oncogene  [52,62]
NOTCH3 notch 3 [80]Oncotarget 2012; 3:  9 - 21 17 www.impactjournals.com/oncotarget
HDAC4 have putative target sites for miR-133a or miR-
133b, whereas miR-133b target; BCL2L2 also has putative 
miR-1 or miR-206 target sites. These facts suggest that 
miR-1/miR-133a and miR-206/miR-133b clusters might 
coordinately affect downstream pathways.
Computational analysis of miR-1-, miR-133a-, 
miR-133b- and miR-206-regulated molecular 
networks
To reveal the biological significance of these clusters, 
a list of predicted targets of miR-1 or miR-206 and miR-
133a or miR-133b was constructed using TargetScan 
(Additional Table 1). Putative miR-1 or miR-206 targets 
exist in 2498 genes, and putative miR-133a or miR-133b 
targets are found in 1756 genes. The total number of genes 
targeted by miR-1 or miR-206 and miR-133a or miR-133b 
is 3716. Common targets of miR-1 or miR-206 and miR-
133a or miR-133b are 538 genes, which is 21.5% of miR-
1 or miR-206 targets and 30.6% of miR-133a or miR-133b 
targets (Additional Table 1).
To identify the biological processes or pathways 
potentially regulated by the miR-1/miR-133a and miR-
206/miR-133b clusters, we performed GENECODIS 
analysis [81,82] with our predicted target list. The 
GENECODIS analysis revealed many signaling pathways 
(Figure 5). Several cancers, including PCa, pancreatic 
cancer, lung cancer, AML, RCC, CRC, BC and thyroid 
cancer, are among the statistically enriched categories 
(Additional Table 2), and it is worth mentioning that miR-
1, miR-133a, miR-133b and miR-206 are differentially 
expressed in these types of human malignancies. This 
bioinformatic analysis indicates that the miR-1/miR-
133a and miR-206/miR-133b clusters might supplement 
each other to regulate several cancer pathways, such 
as cell growth, cell apoptosis, cell cycle, invasion and 
angiogenesis (Additional Figure 1). Thus, cooperative 
gene regulation by miRNAs is an interesting subject , 
and it may change our understanding of miRNA-mRNA 
interactions.
CONCLUSION
miRNAs are important modulators of gene 
expression, and they contribute to a variety of biological 
processes, including proliferation, differentiation and 
apoptosis. The  first  evidence  for  their  involvement  in 
cancer was the finding in 2002 that some miRNAs are 
specifically deleted in leukemia . Thereafter, an enormous 
number of articles have been published about miRNAs 
and cancer. Today, nobody doubts that aberrant expression 
of miRNAs causes initiation, development and metastasis 
of human cancers.
Recently, studies from our group and others have 
shown that downregulation of the miR-1/miR-133a and 
miR-206/ miR-133b clusters are frequent events in various 
types of cancer. During evolution of the human genome, 
clustered miRNAs have developed important roles in 
maintaining the functions of the human body. Herein, we 
have reviewed the individual functions of these miRNAs 
and their regulated molecular targets in cooperation or 
independently . Elucidation of the intracellular molecular 
networks regulated by miRNAs is the current difficult 
challenge. Understanding of the molecular networks 
controlled by miRNA clusters may be exploited for future 
cancer treatment.
REFERENCES 
1.  Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell. 2004; 116: 281-97. 
2.  Kloosterman WP, Plasterk RH. The diverse functions of 
microRNAs in animal development and disease. Dev Cell. 
2006; 11: 441-50. 
3.  Tacutu R, Budovsky A, Yanai H, Fraifeld VE. Molecular 
links between cellular senescence, longevity and age-related 
diseases - a systems biology perspective. Aging (Albany 
NY). 2011; 3: 1178-91. 
4.  Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. 
Identification of mammalian microRNA host genes and 
transcription units. Genome Res. 2004; 14: 1902-10. 
5.  Melo SA, Esteller M. A precursor microRNA in a cancer 
cell nucleus: get me out of here! Cell Cycle. 2011; 10: 922-
5. 
6.  Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation 
of the heterochronic gene lin-14 by lin-4 mediates temporal 
pattern formation in C. elegans. Cell. 1993; 75: 855-62. 
7.  Lee RC, Feinbaum RL, Ambros V. The C. elegans 
heterochronic gene lin-4 encodes small RNAs with 
antisense complementarity to lin-14. Cell. 1993; 75: 843-54. 
8.  Filipowicz W, Bhattacharyya SN, Sonenberg N. 
Mechanisms of post-transcriptional regulation by 
microRNAs: are the answers in sight? Nat Rev Genet. 2008; 
9: 102-14. 
9.  Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch 
E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps 
T, Negrini M, Bullrich F, Croce CM. Frequent deletions and 
down-regulation of micro- RNA genes miR15 and miR16 
at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad 
Sci U S A. 2002; 99: 15524-9. 
10.  Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, 
Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, 
Croce CM. Human microRNA genes are frequently located 
at fragile sites and genomic regions involved in cancers. 
Proc Natl Acad Sci U S A. 2004; 101: 2999-3004. Oncotarget 2012; 3:  9 - 21 18 www.impactjournals.com/oncotarget
11.  Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. 
Annu Rev Med. 2009; 60: 167-79. 
12.  Nelson  KM,  Weiss  GJ.  MicroRNAs  and  cancer:  past, 
present, and potential future. Mol Cancer Ther. 2008; 7: 
3655-60. 
13.  Inui M, Martello G, Piccolo S. MicroRNA control of signal 
transduction. Nat Rev Mol Cell Biol. 2010; 11: 252-63. 
14. Ory B, Ellisen LW. A microRNA-dependent circuit 
controlling p63/p73 homeostasis: p53 family cross-talk 
meets therapeutic opportunity. Oncotarget. 2011; 2: 259-64. 
15.  Noonan EJ, Place RF, Basak S, Pookot D, Li LC. miR-449a 
causes Rb-dependent cell cycle arrest and senescence in 
prostate cancer cells. Oncotarget. 2010; 1: 349-58. 
16.  Erkan EP, Breakefield XO, Saydam O. miRNA signature 
of schwannomas: possible role(s) of “tumor suppressor” 
miRNAs in benign tumors. Oncotarget. 2011; 2: 265-70. 
17.  Davis BN, Hata A. microRNA in Cancer---The involvement 
of aberrant microRNA biogenesis regulatory pathways. 
Genes Cancer. 2010; 1: 1100-14. 
18.  Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with 
a role in cancer. Nat Rev Cancer. 2006; 6: 259-69. 
19.  Mavrakis KJ, Leslie CS, Wendel HG. Cooperative control 
of tumor suppressor genes by a network of oncogenic 
microRNAs. Cell Cycle. 2011; 10: 2845-9. 
20.  Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 
in cancer: discovery, function and future perspectives. Cell 
Death Differ. 2010; 17: 215-20. 
21.  Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in 
the midst of the cancer network. Int J Biochem Cell Biol. 
2010; 42: 1348-54. 
22.  Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, 
Aravin A, Brownstein MJ, Tuschl T, Margalit H. Clustering 
and conservation patterns of human microRNAs. Nucleic 
Acids Res. 2005; 33: 2697-706. 
23.  Ambros V. The functions of animal microRNAs. Nature. 
2004; 431: 350-5. 
24.  Callis TE, Wang DZ. Taking microRNAs to heart. Trends 
Mol Med. 2008; 14: 254-60. 
25.  Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 
133, and 206: critical factors of skeletal and cardiac muscle 
development, function, and disease. Int J Biochem Cell 
Biol. 2010; 42: 1252-5. 
26.  Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, 
Hammond SM, Conlon FL, Wang DZ. The role of 
microRNA-1 and microRNA-133 in skeletal muscle 
proliferation and differentiation. Nat Genet. 2006; 38: 228-
33. 
27.  Baskerville  S,  Bartel  DP.  Microarray  profiling  of 
microRNAs reveals frequent coexpression with neighboring 
miRNAs and host genes. RNA. 2005; 11: 241-7. 
28.  Yu J, Wang F, Yang GH, Wang FL, Ma YN, Du ZW, Zhang 
JW. Human microRNA clusters: genomic organization and 
expression profile in leukemia cell lines. Biochem Biophys 
Res Commun. 2006; 349: 59-68. 
29.  Brett JO, Renault VM, Rafalski VA, Webb AE, Brunet 
A. The microRNA cluster miR-106b~25 regulates adult 
neural stem/progenitor cell proliferation and neuronal 
differentiation. Aging (Albany NY). 2011; 3: 108-24. 
30. Chhabra R, Dubey R, Saini N. Cooperative and 
individualistic functions of the microRNAs in the miR-
23a~27a~24-2 cluster and its implication in human diseases. 
Mol Cancer. 2010; 9: 232. 
31.  Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt 
K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban 
R,  Krauthammer  M,  Tuck  D,  Slack  FJ,  Weidhaas  JB. 
MicroRNA signatures differentiate melanoma subtypes. 
Cell Cycle. 2011; 10: 1845-52. 
32.  Chan E, Prado DE, Weidhaas JB. Cancer microRNAs: 
from subtype profiling to predictors of response to therapy. 
Trends Mol Med. 2011; 17: 235-43. 
33.  Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival 
prediction of gastric cancer by a seven-microRNA 
signature. Gut. 2010; 59: 579-85. 
34.  Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri 
F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti 
LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia 
S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes 
KR,  Abruzzo  LV,  Keating  MJ,  Calin  GA.  microRNA 
fingerprinting  of  CLL  patients  with  chromosome  17p 
deletion  identify  a  miR-21  score  that  stratifies  early 
survival. Blood. 2010; 116: 945-52. 
35.  Radojicic  J,  Zaravinos  A,  Vrekoussis  T,  Kafousi  M, 
Spandidos DA, Stathopoulos EN. MicroRNA expression 
analysis in triple-negative (ER, PR and Her2/neu) breast 
cancer. Cell Cycle. 2011; 10: 507-17. 
36.  Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman 
E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, 
Krichevsky AM, Noske DP, Tannous BA, Wurdinger T. 
miR-101 is down-regulated in glioblastoma resulting in 
EZH2-induced proliferation, migration, and angiogenesis. 
Oncotarget. 2010; 1: 710-20. 
37. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska 
I, Delgado M, De Las Rivas J, Ticona FV, Ferminan E, 
Martin-Jimenez P, Chillon C, Risueno A, Hernandez JM, 
Garcia-Sanz R, Gonzalez M, San Miguel JF. Deregulation 
of microRNA expression in the different genetic subtypes 
of multiple myeloma and correlation with gene expression 
profiling. Leukemia. 2010; 24: 629-37. 
38.  Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Sasaki 
K, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, 
Nakagawa M, Okamoto Y, Seki N. Identification of novel 
molecular targets regulated by tumor suppressive miR-1/
miR-133a in maxillary sinus squamous cell carcinoma. Int 
J Oncol. 2011; 39: 1099-107. 
39. Kawakami K, Enokida H, Chiyomaru T, Tatarano 
S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, 
Nishiyama K, Nohata N, Seki N, Nakagawa M. The Oncotarget 2012; 3:  9 - 21 19 www.impactjournals.com/oncotarget
functional significance of miR-1 and miR-133a in renal 
cell carcinoma. Eur J Cancer. 2011; [Epub ahead of print] 
PMID: 21745735.
40. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, 
Shepherd CJ, Shipley J, Lodish HF. Distinct roles for miR-
1 and miR-133a in the proliferation and differentiation of 
rhabdomyosarcoma cells. FASEB J. 2010; 24: 3427-37. 
41.  Datta  J,  Kutay  H,  Nasser  MW,  Nuovo  GJ,  Wang  B, 
Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen 
TD, Ghoshal K, Jacob ST. Methylation mediated silencing 
of MicroRNA-1 gene and its role in hepatocellular 
carcinogenesis. Cancer Res. 2008; 68: 5049-58. 
42.  Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima 
M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, 
Shinomura Y, Imai K, Toyota M. Genome-wide profiling 
of chromatin signatures reveals epigenetic regulation of 
MicroRNA genes in colorectal cancer. Cancer Res. 2011; 
71: 5646-58. 
43.  Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, 
Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K. 
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. 
Suppression of tumorigenic property of lung cancer cells 
and their sensitization to doxorubicin-induced apoptosis by 
miR-1. J Biol Chem. 2008; 283: 33394-405. 
44.  Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, 
Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen 
CL, Zieger K, Kauppinen S, Ulhoi BP, Kjems J, Borre M, 
Orntoft TF. Genomic profiling of microRNAs in bladder 
cancer: miR-129 is associated with poor outcome and 
promotes cell death in vitro. Cancer Res. 2009; 69: 4851-
60. 
45.  Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata 
DM, Xie H, Lindforss U, Olivecrona H, Lui WO. miR-
185 and miR-133b deregulation is associated with overall 
survival and metastasis in colorectal cancer. Int J Oncol. 
2011; 39: 311-8. 
46.  Missiaglia E, Shepherd CJ, Patel S, Thway K, Pierron G, 
Pritchard-Jones K, Renard M, Sciot R, Rao P, Oberlin O, 
Delattre O, Shipley J. MicroRNA-206 expression levels 
correlate with clinical behaviour of rhabdomyosarcomas. 
Br J Cancer. 2010; 102: 1769-77. 
47.  Brase  JC,  Wuttig  D,  Kuner  R,  Sultmann  H.  Serum 
microRNAs as non-invasive biomarkers for cancer. Mol 
Cancer. 2010; 9: 306. 
48.  Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in 
body fluid: a new potential biomarker for cancer diagnosis 
and prognosis. Cancer Sci. 2010; 101: 2087-92. 
49.  Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu 
L, Zen K, Zhang C, Shen H. Serum microRNA signatures 
identified in a genome-wide serum microRNA expression 
profiling predict survival of non-small-cell lung cancer. J 
Clin Oncol. 2010; 28: 1721-6. 
50.  Miyachi M, Tsuchiya K, Yoshida H, Yagyu S, Kikuchi K, 
Misawa A, Iehara T, Hosoi H. Circulating muscle-specific 
microRNA, miR-206, as a potential diagnostic marker for 
rhabdomyosarcoma. Biochem Biophys Res Commun. 2010; 
400: 89-93. 
51.  Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, 
Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang 
S, Zen K, Ba Y, Zhang CY. A five-microRNA signature 
identified from genome-wide serum microRNA expression 
profiling serves as a fingerprint for gastric cancer diagnosis. 
Eur J Cancer. 2011; 47: 784-91. 
52.  Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, 
Qu J, Tu L. MicroRNA-1/206 targets c-Met and inhibits 
rhabdomyosarcoma development. J Biol Chem. 2009; 284: 
29596-604. 
53.  Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, 
Yoshino H, Chiyomaru T, Kawakami K, Enokida H, 
Nakagawa M, Shozu M, Okamoto T, Seki N. miR-1 as a 
tumor suppressive microRNA targeting TAGLN2 in head 
and neck squamous cell carcinoma. Oncotarget. 2011; 2: 
29-44. 
54.  Wang F, Song G, Liu M, Li X, Tang H. miRNA-1 targets 
fibronectin1 and suppresses the migration and invasion of 
the HEp2 laryngeal squamous carcinoma cell line. FEBS 
Lett. 2011; 585: 3263-9. 
55. Leone V, D’Angelo D, Ferraro A, Pallante P, Rubio 
I, Santoro M, Croce CM, Fusco A. A TSH-CREB1-
microRNA loop is required for thyroid cell growth. Mol 
Endocrinol. 2011; 25: 1819-30. 
56.  Leone V, D’Angelo D, Rubio I, de Freitas PM, Federico A, 
Colamaio M, Pallante P, Medeiros-Neto G, Fusco A. MiR-
1 is a tumor suppressor in thyroid carcinogenesis targeting 
CCND2,  CXCR4,  and  SDF-1alpha.  J  Clin  Endocrinol 
Metab. 2011; 96: E1388-98. 
57.  Yip  L,  Kelly  L,  Shuai  Y,  Armstrong  MJ,  Nikiforov 
YE, Carty SE, Nikiforova MN. MicroRNA signature 
distinguishes the degree of aggressiveness of papillary 
thyroid carcinoma. Ann Surg Oncol. 2011; 18: 2035-41. 
58.  Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida 
H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, 
Seki N. Tumour suppressors miR-1 and miR-133a target 
the oncogenic function of purine nucleoside phosphorylase 
(PNP) in prostate cancer. Br J Cancer. 2011; 2012; 106: 
405-13.
59. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, 
Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M. 
The tumour-suppressive function of miR-1 and miR-133a 
targeting TAGLN2 in bladder cancer. Br J Cancer. 2011; 
104: 808-18. 
60.  Wu CD, Kuo YS, Wu HC, Lin CT. MicroRNA-1 induces 
apoptosis by targeting prothymosin alpha in nasopharyngeal 
carcinoma cells. J Biomed Sci. 2011; 18: 80. 
61.  Gomez-Benito M, Conchillo A, Garcia MA, Vazquez I, 
Maicas M, Vicente C, Cristobal I, Marcotegui N, Garcia-
Orti L, Bandres E, Calasanz MJ, Alonso MM, Odero MD. 
EVI1 controls proliferation in acute myeloid leukaemia Oncotarget 2012; 3:  9 - 21 20 www.impactjournals.com/oncotarget
through modulation of miR-1-2. Br J Cancer. 2010; 103: 
1292-6. 
62.  Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, 
Ladanyi M, Tuschl T, Ponzetto C. The muscle-specific 
microRNA miR-206 blocks human rhabdomyosarcoma 
growth in xenotransplanted mice by promoting myogenic 
differentiation. J Clin Invest. 2009; 119: 2366-78. 
63.  Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-
Paananen S, Kleivi K, Enerly E, Aakula A, Hellstrom K, 
Sahlberg N, Kristensen VN, Borresen-Dale AL, Saviranta 
P, Perala M, Kallioniemi O. Protein lysate microarray 
analysis to identify microRNAs regulating estrogen receptor 
signaling in breast cancer cell lines. Oncogene. 2009; 28: 
3926-36. 
64.  Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. 
miR-206 Expression is down-regulated in estrogen receptor 
alpha-positive human breast cancer. Cancer Res. 2008; 68: 
5004-8. 
65.  Chen X, Yan Q, Li S, Zhou L, Yang H, Yang Y, Liu 
X, Wan X. Expression of the tumor suppressor miR-
206 is associated with cellular proliferative inhibition 
and impairs invasion in ERalpha-positive endometrioid 
adenocarcinoma. Cancer Lett. 2012; 314: 41-53. 
66.  Wang  X,  Ling  C,  Bai  Y,  Zhao  J.  MicroRNA-206  is 
associated with invasion and metastasis of lung cancer. 
Anat Rec (Hoboken). 2011; 294: 88-92. 
67.  Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto 
T, Yoshida S, Suzuki M, Yoshino I, Seki N. Tumor 
suppressive microRNA-133a regulates novel molecular 
networks in lung squamous cell carcinoma. J Hum Genet. 
2012; 57: 38-45.
68.  Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, 
Wai-Man Ng R, Ignace Wei W. Identification of pyruvate 
kinase type M2 as potential oncoprotein in squamous cell 
carcinoma of tongue through microRNA profiling. Int J 
Cancer. 2008; 123: 251-7. 
69.  Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, 
Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, 
Matsubara H. miR-145, miR-133a and miR-133b: Tumor 
suppressive miRNAs target FSCN1 in esophageal squamous 
cell carcinoma. Int J Cancer. 2010; 127: 2804-14. 
70.  Hu G, Chen D, Li X, Yang K, Wang H, Wu W. miR-133b 
regulates the MET proto-oncogene and inhibits the growth 
of colorectal cancer cells in vitro and in vivo. Cancer Biol 
Ther. 2010; 10: 190-7. 
71.  Mavrakis  KJ,  Wendel  HG.  TargetScreen:  an  unbiased 
approach to identify functionally important microRNA 
targets. Cell Cycle. 2010; 9: 2080-4. 
72.  Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida 
Y, Kawahara K, Nishiyama K, Seki N, Nakagawa M. 
Functional role of LASP1 in cell viability and its regulation 
by microRNAs in bladder cancer. Urol Oncol. 2010; [Epub 
ahead of print] PMID: 20843712.
73.  Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka 
H, Yamasaki T, Gotannda T, Tachiwada T, Nohata N, 
Yamane T, Seki N, Nakagawa M. Tumor suppressive 
microRNA-1 mediated novel apoptosis pathways through 
direct inhibition of splicing factor arginine/serine-rich 9 
(SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res 
Commun. 2012; 417: 588-93.
74.  Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura 
L, Yoshino H, Kawakami K, Chiyomaru T, Enokida H, 
Nakagawa M, Okamoto Y, Seki N. Caveolin-1 mediates 
tumor cell migration and invasion and its regulation by 
miR-133a in head and neck squamous cell carcinoma. Int J 
Oncol. 2011; 38: 209-17. 
75. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, 
Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, 
Nakagawa M. miR-145 and miR-133a function as tumour 
suppressors and directly regulate FSCN1 expression in 
bladder cancer. Br J Cancer. 2010; 102: 883-91. 
76. Mutallip M, Nohata N, Hanazawa T, Kikkawa N, 
Horiguchi S, Fujimura L, Kawakami K, Chiyomaru T, 
Enokida H, Nakagawa M, Okamoto Y, Seki N. Glutathione 
S-transferase P1 (GSTP1) suppresses cell apoptosis and its 
regulation by miR-133alpha in head and neck squamous 
cell carcinoma (HNSCC). Int J Mol Med. 2011; 27: 345-52. 
77. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, 
Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa 
M. MiR-133a induces apoptosis through direct regulation 
of GSTP1 in bladder cancer cell lines. Urol Oncol. 2011; 
[Epub ahead of print] PMID: 21396852.
78.  Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei 
WI. Mature miR-184 as Potential Oncogenic microRNA 
of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 
2008; 14: 2588-92. 
79.  Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, 
Otterson GA, Nana-Sinkam SP. MicroRNA 133B targets 
pro-survival molecules MCL-1 and BCL2L2 in lung cancer. 
Biochem Biophys Res Commun. 2009; 388: 483-9. 
80.  Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, 
activates apoptosis, and inhibits tumor cell migration and 
focus formation. J Biol Chem. 2009; 284: 31921-7. 
81.  Carmona-Saez  P,  Chagoyen  M,  Tirado  F,  Carazo  JM, 
Pascual-Montano A. GENECODIS: a web-based tool for 
finding  significant  concurrent  annotations  in  gene  lists. 
Genome Biol. 2007; 8: R3. 
82.  Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente 
C, Yang X, Tirado F, Carazo JM, Pascual-Montano A. 
GeneCodis: interpreting gene lists through enrichment 
analysis and integration of diverse biological information. 
Nucleic Acids Res. 2009; 37: W317-22. 
83.  Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-
Gensler  M,  McLemore  M,  Chen  Q,  Burk  RD,  Smith 
RV,  Prystowsky  MB,  Belbin  TJ,  Schlecht  NF.  Low-
level expression of microRNAs let-7d and miR-205 
are prognostic markers of head and neck squamous cell 
carcinoma. Am J Pathol. 2009; 174: 736-45. Oncotarget 2012; 3:  9 - 21 21 www.impactjournals.com/oncotarget
84.  Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, 
Chazono H, Sakurai D, Horiguchi S, Okamoto Y, Seki N. 
miR-489 is a tumour-suppressive miRNA target PTPN11 
in hypopharyngeal squamous cell carcinoma (HSCC). Br J 
Cancer. 2010; 103: 877-84. 
85.  Wu WY, Xue XY, Chen ZJ, Han SL, Huang YP, Zhang 
LF, Zhu GB, Shen X. Potentially predictive microRNAs 
of gastric cancer with metastasis to lymph node. World J 
Gastroenterol. 2011; 17: 3645-51. 
86.  Szafranska AE, Davison TS, John J, Cannon T, Sipos B, 
Maghnouj A, Labourier E, Hahn SA. MicroRNA expression 
alterations are linked to tumorigenesis and non-neoplastic 
processes in pancreatic ductal adenocarcinoma. Oncogene. 
2007; 26: 4442-52. 
87.  Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong 
J, Cai W, Li H. Differential miRNA expression profiles in 
bladder urothelial carcinomas. Asian Pac J Cancer Prev. 
2010; 11: 905-11. 
88.  Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca 
F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, 
Stephens RM, Croce CM. Genomic profiling of microRNA 
and messenger RNA reveals deregulated microRNA 
expression in prostate cancer. Cancer Res. 2008; 68: 6162-
70. 
89.  Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg 
AL, Silverstein KA, Morlan BW, Riska SM, Boardman 
LA, Cunningham JM, Subramanian S, Wang L, Smyrk 
TC, Rodrigues CM, Thibodeau SN, Steer CJ. Human colon 
cancer  profiles  show  differential  microRNA  expression 
depending on mismatch repair status and are characteristic 
of undifferentiated proliferative states. BMC Cancer. 2009; 
9: 401. 
90.  Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate 
microRNA biomarkers in human colorectal cancer: 
Systematic  review  profiling  studies  and  experimental 
validation. Int J Cancer. 2011; [Epub ahead of print] PMID: 
21671476
91.  Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, 
Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M, 
Garcia-Foncillas J. Identification by Real-time PCR of 13 
mature microRNAs differentially expressed in colorectal 
cancer and non-tumoral tissues. Mol Cancer. 2006; 5: 29. 
92.  Zuker M. Mfold web server for nucleic acid folding and 
hybridization prediction. Nucleic Acids Res. 2003; 31: 
3406-15. 
93.  Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 
KEGG for integration and interpretation of large-scale 
molecular data sets. Nucleic Acids Res. 2012; 40: D109-14.